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Abstract  
Background: Chronic heart failure (CHF) patients can fall into cardiac cachexia (CC), which is marked 
by the decrease of muscle mass and strength. Cardiac cachexia decreases the functional capacity 
and quality of life also increases the length of stay, medical fees, complications, and mortality rate. 
Branched-chain amino acid (BCAA) accounted for 35% of amino acids that build the muscle. We 
hope that BCAA supplementation can increase muscle strength of CHF patients, especially the 
elderly who is more prone to fall into CC. Thus, we performed an evidence-based case report to 
seek an opportunity of BCAA supplementation to an elderly with CHF. 
Objectives: To determine the efficacy of BCAA supplementation on increasing muscle strength in 
CHF patients. 
Methods: Literature searching of the evidence-based case report was performed on Pubmed, 
Cochrane, and Scopus according to the clinical query. Screening on title, abstract, and full text was 
done based on eligibility criteria (meta-analysis or clinical trials, suitability to clinical questions, 
English language, full-text availability, and human studies), followed by duplication filter and critical 
appraisal. 
Results: A randomized-controlled trial was found, but it didn’t find a significant difference between 
the experimental and control groups. 
Conclusions: BCAA supplementation doesn’t give a significant improvement in muscle strength in 
CHF patients. 
Keywords branched-chain amino acid, chronic heart failure, cardiac cachexia, muscle mass, muscle 
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Introduction 
 
Heart failure has become a rising global issue with 
more than 62 million people affected.1 The mortality 
risk is 35% in the first year after diagnosis.2 Despite 
all current and advanced treatment, the 5-year- 
 
mortality rate is still high and increasing.1 The high 
mortality rate allegedly related to anorexia, 
inflammation, and hypermetabolism that occur in 
CHF, which will result in weight loss and loss of 
skeletal muscle mass, called CC. This condition not 
only occurs in the skeletal muscle but also cardiac 
muscle,3 and was estimated to affect between 8 to 
42% of patients with CHF, which responsible to 
increase mortality rate as high as 20-30% at 1 year. 
Therefore, it is crucial to preserve and increase 
muscle mass and strength in CHF patients.4 
Branched-chain amino acid supplementation has 
been shown to enhance muscle’s mitochondrial 
biogenesis by activation of the mechanistic target of 
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rapamycin kinase (mTOR) signaling. Several 
studies have found that BCAA can increase the 
synthesis of protein, reduce the protein breakdown, 
and increase muscle mass in the elderly and several 
catabolic states such as burn and trauma.5 Therefore, 
it is hoped that this report can provide consideration 
for giving BCAA supplementation to alleviate 
cardiac cachexia. 
 
Clinical Scenario 
 
Mr. B, 60 years old, comes with exertional dyspnea 
which worsens since a week ago. He complains 
about orthopnea, fatigue, and ankle edema. He was 
diagnosed with HF with reduced ejection fraction 5 
years ago, after recovering from a heart attack. The 
patient complains about anorexia and low intake, 
which makes his weight drops from 70 kg to 65 kg 
in 6 months. His height is 170 cm, with a calculated 
body mass index of 22.49 kg/m2. Handgrip strength 
found slightly decreased. Other than having an 
elevated CRP (6 mg/dL) and high blood LDL (170 
mg/dL), the other lab result is normal. After treated 
with standard medication for CHF for several days, 
now the patient is stable and ready to be discharged. 
Based on this clinical scenario, a question arises 
whether BCAA supplementation will be effective in 
preserving and increasing muscle mass and strength 
in CHF patients? 
 
Methods 
 
Literature searching was performed on Pubmed, 
Cochrane, and Scopus according to the clinical 
question on the 14th of May 2020. The keywords 
used were “branched-chain amino acid”, “heart 
failure”, “cardiac cachexia”, “muscle mass”, and 
“muscle strength”. Screening on title, abstract, and 
full text was done based on eligibility criteria (meta-
analysis or clinical trials, suitability to clinical 
questions, English language, full-text availability, 
and human studies), followed by duplication filter 
and critical appraisal was shown in Figure 1. A 
critical appraisal is done based on the Center of 
Evidence-Based Medicine, The University of 
Oxford for RCT. 
 
 
 
Results 
 
Following the search strategy, one original article 
was eligible for this evidence-based case report. The 
design and summary of the selected article are 
available in Table 1. Both groups had significant 
improvement in decubitus intolerance, fatigue, 
dyspnea, and muscle strength. But other than a 
marked reduction of hip circumference in the 
experimental group, there was no difference 
statistically between the control and intervention 
group in the rest of anthropometric variables, body 
composition, muscle strength, and physical 
endurance.  
 
Discussion 
 
Studies conducted by Juarez et al6 had a clear 
clinical question (PICO) and corresponded to 
keywords accordingly. The control and intervention 
groups were similar at baseline, except for fatigue 
and cancer history. The assignment of patients to 
treatments was randomized, but not blinded. Aside 
from the allocated treatment, the groups were treated 
equally. Drop-out subjects were not analyzed. 
Overall, we found this study valid, although there 
will still be bias because the assignment is not 
blinded. 
Although there are many studies about protein 
and amino acid supplementation in CHF and CC, 
there is no other study about BCAA 
supplementation. Apparently, this is the first. This 
study did not find any impact on muscle mass and 
strength with BCAA supplementation. The result is 
the same with a study that did not find a difference 
in functional capacity after 5 g/day supplementation 
of carnitine.6 A longitudinal cohort also showed that 
higher protein intake was not associated with 
protection against muscle loss in the elderly. Even 
so, other studies found positive results with amino 
acid supplementation. A study gave 8 g / day of 
essential amino acid and found improvement in 
cardiorespiratory fitness. Other studies found 
amelioration of body weight and muscle mass after 
giving supplementation of 600 kcal and 20 g of 
protein per day.7  
There are several presumptions about this 
study’s result. First of all, perhaps the participants 
were not in a depleted state of BCAA, so they could 
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not benefit from BCAA supplementation.7 
Secondly, excess of BCAA in the blood can cause a 
rise in BCAA’s metabolite, branched-chain-α-
ketoacid (BCKA) which can cause elevated levels of 
ammonia in blood and result in metabolic acidosis. 
This condition can create mitochondrial 
dysfunction, oxidative stress, and harm myocyte.1 
Thirdly, the hyper catabolic state of heart failure 
patients may cause a decrease in gastrointestinal 
tract absorption, thus BCAA can not be absorbed 
optimally. This is seen from the increasing level of 
BUN and urea in the intervention group.6 Last but 
not least, it is plausible that in the elderly with 
cardiac cachexia, BCAA supplementation is not 
enough to increase muscle mass without strength 
training.7 However, strength training did not include 
in other studies, they only gave protein or amino acid 
supplementation. This study is the first to 
accommodate strength training with BCAA 
supplementation. The limitation of this study is the 
assignment is not blinded, and perhaps it will be 
fairer to look at the true effect of BCAA 
supplementation if the assignment of the groups 
doesn’t involve strength training. For example, the 
experimental group is given BCAA 
supplementation, and the control group is not. 
 
Conclusion 
 
Although we can not recommend BCAA 
supplementation for CHF patients to prevent CC in 
the present, more study and evidence are needed to 
identify the efficacy of BCAA to prevent and treat 
CC in CHF. 
 
Table 1. Literature characteristic 
Article Design Population Exposure Results 
Pineda-
Juarez et 
al, 20166 
Randomized 
controlled trial 
66 patients aged >18 
years old from the 
heart failure clinic in 
Mexico City who had 
stable heart failure, no 
myocardial 
revascularization, 
unstable angina, or 
stroke in the previous 
3 months, had no other 
chronic illness which 
contributed to a loss of 
muscle mass, and able 
to perform an exercise 
The intervention 
group had a 
personalized 
diet, a resistance 
exercise 
program (RE), 
and 20 grams of 
BCAA per day 
for 3 months. 
Control group 
only had a 
personalized 
diet and RE 
program 
There were statistically significant 
improvements in decubitus intolerance, 
dyspnea (p=0.03), fatigue (p<0.0001), and a 
tendency to decreased dyspnea (p=0.07) in 2 
groups, but there was no statistical difference 
between the groups. 
Muscle strength was increased by 34.5% in 
the subjects (p=0.08), with no difference 
between groups. 
Hip circumference in the experimental group 
was decreased markedly than the control 
group (p=0.02). But the differences between 
other anthropometric variables, body 
composition, and physical endurance were 
not statistically different between the two 
groups. 
*BCAA = branched-chain amino acid 
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Figure 1. Flowchart of search strategy 
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